What is Angiodynamics's earnings per share (EPS)?

Angiodynamics (ANGO) reported diluted earnings per share of $-0.83 for fiscal year 2025. This represents a 81.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Angiodynamics Financials

ANGO

Source SEC Filings (10-K/10-Q) Updated Apr 2, 2026 Currency USD FYE May

This page shows Angiodynamics (ANGO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 29/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Angiodynamics has an operating margin of -13.7%, meaning the company retains $-14 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -63.3% the prior year.

Growth

Angiodynamics's revenue declined 3.8% year-over-year, from $303.9M to $292.5M. This contraction results in a growth score of 27/100.

Leverage

Angiodynamics carries a low D/E ratio of 0.53, meaning only $0.53 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 91/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Angiodynamics's current ratio of 2.21 indicates adequate short-term liquidity, earning a score of 41/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Angiodynamics generated -$10.1M in operating cash flow, capex of $4.5M consumed most of it, leaving -$14.6M in free cash flow. This results in a low score of 13/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Angiodynamics generates a -18.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -89.7% the prior year.

Piotroski F-Score Neutral

5/9

Angiodynamics passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.30x

For every $1 of reported earnings, Angiodynamics generates $0.30 in operating cash flow (-$10.1M OCF vs -$34.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$292.5M

YoY-3.8%

5Y CAGR+2.1%

10Y CAGR-2.0%

Angiodynamics generated $292.5M in revenue in fiscal year 2025. This represents a decrease of 3.8% from the prior year.

EBITDA

-$14.2M

YoY+91.4%

Angiodynamics's EBITDA was -$14.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 91.4% from the prior year.

Net Income

-$34.0M

YoY+81.6%

Angiodynamics reported -$34.0M in net income in fiscal year 2025. This represents an increase of 81.6% from the prior year.

EPS (Diluted)

$-0.83

YoY+81.9%

Angiodynamics earned $-0.83 per diluted share (EPS) in fiscal year 2025. This represents an increase of 81.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$14.6M

YoY+52.4%

Angiodynamics generated -$14.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 52.4% from the prior year.

Cash & Debt

$55.9M

YoY-26.5%

5Y CAGR+0.5%

10Y CAGR+11.8%

Angiodynamics held $55.9M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

41M

YoY+0.9%

5Y CAGR+1.4%

10Y CAGR+1.2%

Angiodynamics had 41M shares outstanding in fiscal year 2025. This represents an increase of 0.9% from the prior year.

Margins & Returns

Gross Margin

53.9%

YoY+3.0pp

5Y CAGR-3.0pp

10Y CAGR+4.6pp

Angiodynamics's gross margin was 53.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.0 percentage points from the prior year.

Operating Margin

-13.7%

YoY+49.7pp

5Y CAGR+49.6pp

10Y CAGR-12.7pp

Angiodynamics's operating margin was -13.7% in fiscal year 2025, reflecting core business profitability. This is up 49.7 percentage points from the prior year.

Net Margin

-11.6%

YoY+49.0pp

5Y CAGR+51.5pp

10Y CAGR-10.7pp

Angiodynamics's net profit margin was -11.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 49.0 percentage points from the prior year.

Return on Equity

-18.6%

YoY+71.1pp

5Y CAGR+18.1pp

10Y CAGR-18.0pp

Angiodynamics's ROE was -18.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 71.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$26.2M

YoY-16.8%

5Y CAGR-2.4%

10Y CAGR-0.1%

Angiodynamics invested $26.2M in research and development in fiscal year 2025. This represents a decrease of 16.8% from the prior year.

Share Buybacks

$1.7M

Angiodynamics spent $1.7M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$4.5M

YoY+77.3%

5Y CAGR-9.2%

10Y CAGR-8.9%

Angiodynamics invested $4.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 77.3% from the prior year.

ANGO Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$292.5M-3.8%	$303.9M-10.3%	$338.8M+7.1%	$316.2M+8.7%	$291.0M+10.2%	$264.2M
Cost of Revenue	$134.8M-9.7%	$149.2M-9.3%	$164.5M+9.3%	$150.5M+12.1%	$134.2M+17.9%	$113.9M
Gross Profit	$157.7M+1.9%	$154.7M-11.2%	$174.2M+5.1%	$165.7M+5.7%	$156.8M+4.3%	$150.3M
R&D Expenses	$26.2M-16.8%	$31.5M+5.5%	$29.9M-2.8%	$30.7M-15.5%	$36.4M+22.6%	$29.7M
SG&A Expenses	$42.1M+2.3%	$41.2M+2.9%	$40.0M+4.0%	$38.5M+7.1%	$35.9M-5.2%	$37.9M
Operating Income	-$40.0M+79.2%	-$192.4M-276.0%	-$51.2M-79.8%	-$28.5M+19.3%	-$35.3M+78.9%	-$167.1M
Interest Expense	N/A	-$1.6M-159.7%	$2.7M+292.7%	$688K-20.1%	$861K-5.1%	$907K
Income Tax	-$39K+99.5%	-$7.3M-265.4%	-$2.0M+41.4%	-$3.4M+24.5%	-$4.5M-234.1%	-$1.3M
Net Income	-$34.0M+81.6%	-$184.3M-251.5%	-$52.4M-97.5%	-$26.5M+15.9%	-$31.5M+81.1%	-$166.8M
EPS (Diluted)	$-0.83+81.9%	$-4.59-245.1%	$-1.33-95.6%	$-0.68+17.1%	$-0.82+81.3%	$-4.39

Metric	Q4'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$78.4M-1.3%	$79.4M+4.9%	$75.7M-5.5%	$80.2M+11.3%	$72.0M-1.2%	$72.8M+7.9%	$67.5M-4.9%	$71.0M
Cost of Revenue	$36.9M+6.6%	$34.6M+2.4%	$33.9M-10.8%	$37.9M+14.5%	$33.1M+0.6%	$32.9M+7.1%	$30.8M-5.2%	$32.5M
Gross Profit	$41.5M-7.4%	$44.8M+7.0%	$41.9M-0.9%	$42.2M+8.6%	$38.9M-2.6%	$39.9M+8.7%	$36.7M-4.7%	$38.5M
R&D Expenses	$7.1M-8.8%	$7.8M+21.1%	$6.4M-2.6%	$6.6M-4.7%	$6.9M+7.4%	$6.4M+2.4%	$6.3M-6.5%	$6.7M
SG&A Expenses	$10.7M+5.6%	$10.2M-19.1%	$12.6M+22.7%	$10.2M-2.4%	$10.5M+1.0%	$10.4M-5.3%	$11.0M+5.1%	$10.4M
Operating Income	-$13.0M-111.4%	-$6.1M+42.5%	-$10.7M-84.1%	-$5.8M+42.0%	-$10.0M+10.1%	-$11.1M+15.3%	-$13.1M+9.4%	-$14.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$567K
Income Tax	$12K+340.0%	-$5K-107.7%	$65K+208.3%	-$60K-2900.0%	-$2K+98.2%	-$110K-182.7%	$133K+119.2%	-$692K
Net Income	-$8.1M-27.3%	-$6.3M+41.8%	-$10.9M-80.2%	-$6.0M-37.3%	-$4.4M+59.0%	-$10.7M+16.1%	-$12.8M+4.8%	-$13.4M
EPS (Diluted)	$-0.19-26.7%	$-0.15+42.3%	$-0.26	N/A	$-0.11+57.7%	$-0.26+16.1%	$-0.31	N/A

ANGO Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$280.1M-11.8%	$317.7M-40.4%	$532.6M-3.6%	$552.8M-1.5%	$561.4M-5.5%	$594.2M
Current Assets	$168.3M-12.9%	$193.3M+18.2%	$163.5M+14.1%	$143.3M+1.8%	$140.9M-7.9%	$152.9M
Cash & Equivalents	$55.9M-26.5%	$76.1M+70.5%	$44.6M+54.8%	$28.8M-40.1%	$48.2M-11.5%	$54.4M
Inventory	$62.0M+2.3%	$60.6M+9.6%	$55.3M+7.7%	$51.4M+5.7%	$48.6M-18.8%	$59.9M
Accounts Receivable	$42.9M-1.7%	$43.6M-17.4%	$52.8M+1.0%	$52.3M+47.7%	$35.4M+13.2%	$31.3M
Goodwill	N/A	$0-100.0%	$159.2M-20.8%	$201.1M-0.1%	$201.3M+0.4%	$200.5M
Total Liabilities	$97.2M-13.3%	$112.1M-27.4%	$154.3M+20.3%	$128.3M+5.1%	$122.0M-12.5%	$139.3M
Current Liabilities	$76.2M-16.4%	$91.2M+8.7%	$83.8M+12.8%	$74.3M+29.1%	$57.6M+11.9%	$51.4M
Long-Term Debt	N/A	$0-100.0%	$49.8M+99.3%	$25.0M	N/A	N/A
Total Equity	$183.0M-11.0%	$205.6M-45.7%	$378.3M-10.9%	$424.5M-3.4%	$439.5M-3.4%	$454.9M
Retained Earnings	-$429.2M-8.6%	-$395.2M-87.4%	-$210.9M-33.1%	-$158.4M-20.1%	-$131.9M-31.4%	-$100.3M

Metric	Q4'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$260.7M-3.3%	$269.7M+1.5%	$265.6M-5.2%	$280.1M-1.8%	$285.4M-2.1%	$291.6M-0.7%	$293.6M-7.6%	$317.7M
Current Assets	$155.6M-3.6%	$161.3M+3.0%	$156.7M-6.9%	$168.3M-2.3%	$172.3M-1.8%	$175.4M+1.6%	$172.6M-10.7%	$193.3M
Cash & Equivalents	$37.8M-9.2%	$41.6M+7.4%	$38.8M-30.6%	$55.9M+24.9%	$44.8M-17.2%	$54.1M-1.7%	$55.0M-27.7%	$76.1M
Inventory	$58.6M-10.7%	$65.6M+5.3%	$62.3M+0.4%	$62.0M-1.7%	$63.1M-4.3%	$65.9M+1.9%	$64.7M+6.7%	$60.6M
Accounts Receivable	$45.6M+2.5%	$44.4M+4.2%	$42.6M-0.6%	$42.9M-1.3%	$43.5M+0.7%	$43.2M+9.1%	$39.6M-9.3%	$43.6M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Total Liabilities	$87.3M-6.5%	$93.3M+7.6%	$86.8M-10.7%	$97.2M-2.4%	$99.5M-5.0%	$104.8M+8.0%	$97.0M-13.4%	$112.1M
Current Liabilities	$66.1M-8.2%	$72.0M+5.4%	$68.3M-10.4%	$76.2M-2.3%	$78.0M-12.0%	$88.6M+15.5%	$76.7M-15.9%	$91.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Total Equity	$173.4M-1.7%	$176.3M-1.4%	$178.9M-2.2%	$183.0M-1.6%	$185.9M-0.5%	$186.8M-5.0%	$196.6M-4.4%	$205.6M
Retained Earnings	-$454.5M-1.8%	-$446.4M-1.4%	-$440.1M-2.5%	-$429.2M-1.4%	-$423.1M-1.1%	-$418.7M-2.6%	-$408.0M-3.2%	-$395.2M

ANGO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$10.1M+64.0%	-$28.2M-36200.0%	$78K+101.1%	-$7.2M-129.9%	$24.1M+265.5%	-$14.6M
Capital Expenditures	$4.5M+77.3%	$2.5M-33.9%	$3.8M-11.3%	$4.3M-17.2%	$5.2M-28.3%	$7.2M
Free Cash Flow	-$14.6M+52.4%	-$30.7M-721.5%	-$3.7M+67.5%	-$11.5M-160.8%	$18.9M+186.8%	-$21.8M
Investing Cash Flow	-$10.2M-108.2%	$123.7M+1369.4%	-$9.7M+49.5%	-$19.3M-40.8%	-$13.7M+78.4%	-$63.3M
Financing Cash Flow	-$255K+99.6%	-$64.2M-352.7%	$25.4M+230.9%	$7.7M+145.2%	-$17.0M+82.2%	-$95.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$1.7M	$0	$0	N/A	N/A	N/A

Metric	Q4'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$3.1M-166.7%	$4.7M+129.3%	-$15.9M-184.6%	$18.8M+243.0%	-$13.2M-632.1%	$2.5M+113.5%	-$18.3M-465.0%	$5.0M
Capital Expenditures	$1.0M+140.5%	$422K-42.3%	$731K-5.9%	$777K-56.8%	$1.8M+125.6%	$797K-27.0%	$1.1M+92.9%	$566K
Free Cash Flow	-$4.1M-197.3%	$4.2M+125.5%	-$16.6M-192.3%	$18.0M+220.6%	-$15.0M-992.4%	$1.7M+108.7%	-$19.3M-536.2%	$4.4M
Investing Cash Flow	-$1.5M+7.0%	-$1.6M-4.5%	-$1.6M+40.9%	-$2.6M+17.7%	-$3.2M-62.6%	-$2.0M+18.5%	-$2.4M-3.0%	-$2.3M
Financing Cash Flow	$621K+775.0%	-$92K-164.3%	$143K+102.5%	-$5.8M-180.7%	$7.1M+736.4%	-$1.1M-120.6%	-$509K+89.8%	-$5.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$1.7M	$0	$0	$0	$0-100.0%	$1.1M+102.5%	$552K	$0

ANGO Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	53.9%+3.0pp	50.9%-0.5pp	51.4%-1.0pp	52.4%-1.5pp	53.9%-3.0pp	56.9%
Operating Margin	-13.7%+49.7pp	-63.3%-48.2pp	-15.1%-6.1pp	-9.0%+3.1pp	-12.1%+51.1pp	-63.3%
Net Margin	-11.6%+49.0pp	-60.7%-45.2pp	-15.5%-7.1pp	-8.4%+2.4pp	-10.8%+52.3pp	-63.1%
Return on Equity	-18.6%+71.1pp	-89.7%-75.8pp	-13.9%-7.6pp	-6.3%+0.9pp	-7.2%+29.5pp	-36.7%
Return on Assets	-12.1%+45.9pp	-58.0%-48.2pp	-9.8%-5.1pp	-4.8%+0.8pp	-5.6%+22.4pp	-28.1%
Current Ratio	2.21+0.1	2.12+0.2	1.95+0.0	1.93-0.5	2.45-0.5	2.97
Debt-to-Equity	0.53+0.5	0.00-0.1	0.13+0.1	0.06-0.2	0.28-0.0	0.31
FCF Margin	-5.0%+5.1pp	-10.1%-9.0pp	-1.1%+2.5pp	-3.6%-10.1pp	6.5%+14.8pp	-8.3%

Metric	Q4'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	52.9%-3.5pp	56.4%+1.1pp	55.3%+2.6pp	52.7%-1.3pp	54.0%-0.8pp	54.8%+0.4pp	54.4%+0.2pp	54.3%
Operating Margin	-16.5%-8.8pp	-7.7%+6.4pp	-14.1%-6.8pp	-7.2%+6.6pp	-13.9%+1.4pp	-15.2%+4.2pp	-19.4%+1.0pp	-20.4%
Net Margin	-10.3%-2.3pp	-8.0%+6.4pp	-14.4%-6.8pp	-7.5%-1.4pp	-6.1%+8.6pp	-14.7%+4.2pp	-19.0%0.0pp	-18.9%
Return on Equity	-4.7%-1.1pp	-3.6%+2.5pp	-6.1%-2.8pp	-3.3%-0.9pp	-2.4%+3.4pp	-5.8%+0.8pp	-6.5%+0.0pp	-6.5%
Return on Assets	-3.1%-0.8pp	-2.4%+1.8pp	-4.1%-1.9pp	-2.2%-0.6pp	-1.5%+2.1pp	-3.7%+0.7pp	-4.4%-0.1pp	-4.2%
Current Ratio	2.35+0.1	2.24-0.1	2.29+0.1	2.210.0	2.21+0.2	1.98-0.3	2.25+0.1	2.12
Debt-to-Equity	0.50-0.0	0.53+0.0	0.49-0.0	0.530.0	0.54-0.0	0.56+0.1	0.49+0.5	0.00
FCF Margin	-5.3%-10.6pp	5.3%+27.3pp	-22.0%-44.5pp	22.5%+43.3pp	-20.8%-23.1pp	2.3%+31.0pp	-28.7%-34.9pp	6.3%

Similar Companies

Sanara Medtech Inc SMTI

$158.0M

Embecta Corp EMBC

$524.1M

KESTRA MED TECHNOLOGIES LTD KMTS

$1.2B

Staar Surg STAA

$1.0B

Atricure ATRC

$1.4B

Frequently Asked Questions

What is Angiodynamics's annual revenue?

Angiodynamics (ANGO) reported $292.5M in total revenue for fiscal year 2025. This represents a -3.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Angiodynamics's revenue growing?

Angiodynamics (ANGO) revenue declined by 3.8% year-over-year, from $303.9M to $292.5M in fiscal year 2025.

Is Angiodynamics profitable?

No, Angiodynamics (ANGO) reported a net income of -$34.0M in fiscal year 2025, with a net profit margin of -11.6%.

What is Angiodynamics's EBITDA?

Angiodynamics (ANGO) had EBITDA of -$14.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Angiodynamics's gross margin?

Angiodynamics (ANGO) had a gross margin of 53.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Angiodynamics's operating margin?

Angiodynamics (ANGO) had an operating margin of -13.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Angiodynamics's net profit margin?

Angiodynamics (ANGO) had a net profit margin of -11.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Angiodynamics's return on equity (ROE)?

Angiodynamics (ANGO) has a return on equity of -18.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Angiodynamics's free cash flow?

Angiodynamics (ANGO) generated -$14.6M in free cash flow during fiscal year 2025. This represents a 52.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Angiodynamics's operating cash flow?

Angiodynamics (ANGO) generated -$10.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Angiodynamics's total assets?

Angiodynamics (ANGO) had $280.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Angiodynamics's capital expenditures?

Angiodynamics (ANGO) invested $4.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Angiodynamics spend on research and development?

Angiodynamics (ANGO) invested $26.2M in research and development during fiscal year 2025.

Does Angiodynamics buy back shares?

Yes, Angiodynamics (ANGO) spent $1.7M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Angiodynamics have outstanding?

Angiodynamics (ANGO) had 41M shares outstanding as of fiscal year 2025.

What is Angiodynamics's current ratio?

Angiodynamics (ANGO) had a current ratio of 2.21 as of fiscal year 2025, which is generally considered healthy.

What is Angiodynamics's debt-to-equity ratio?

Angiodynamics (ANGO) had a debt-to-equity ratio of 0.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Angiodynamics's return on assets (ROA)?

Angiodynamics (ANGO) had a return on assets of -12.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Angiodynamics's cash runway?

Based on fiscal year 2025 data, Angiodynamics (ANGO) had $55.9M in cash against an annual operating cash burn of $10.1M. This gives an estimated cash runway of approximately 66 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Angiodynamics's Piotroski F-Score?

Angiodynamics (ANGO) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Angiodynamics's earnings high quality?

Angiodynamics (ANGO) has an earnings quality ratio of 0.30x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Angiodynamics?

Angiodynamics (ANGO) scores 29 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.